Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

Fig. 4

Effect of ALX-0061 on total (a) and free (b) sIL-6R plasma levels in cynomolgus monkeys. Per group, mean plasma concentrations of either biomarker ± SD are shown (n = 2 for vehicle group; n = 3 for dosing groups). Placebo or ALX-0061 at given doses were administered at day 0 as a single intravenous administration to non-stimulated cynomolgus monkeys. n: number of animals; SD: standard deviation; sIL-6R: soluble IL-6R

Back to article page